Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| TuHURA Biosciences Inc. | VAL-083 | Newly diagnosed MGMT-unmethylated Glioblastoma Multiform (GBM) | Phase 2 | Trial Completed | Intravenous | Oncology |
| TuHURA Biosciences Inc. | VAL-083 | Newly diagnosed MGMT-unmethylated Glioblastoma Multiform (GBM) | Phase 2 | Trial Completed | Intravenous | Oncology |
| TuHURA Biosciences Inc. | TBS-2025 - (VISTA) | Acute Myeloid Leukemia (AML) | Phase 2 | Trial Planned | intravenous | Oncology |
| Tvardi Therapeutics Inc. | KORSUVA (CR845/difelikefalin) oral - (KICK) | Stage 3-4 Chronic Kidney Disease-Associated Pruritus | Phase 3 | Trial Discontinued | Oral | N/A |
| Tvardi Therapeutics Inc. | KORSUVA (CR845/difelikefalin) injection - (KALM-1) | Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus | Phase 3 | Trial Discontinued | Intravenous | N/A |
| Tvardi Therapeutics Inc. | Oral KORSUVA (difelikefalin injection) - (KOURAGE 1) | Pruritus and Notalgia Paresthetica | Phase 2/3 | Trial Discontinued | Intravenous | N/A |
| Tvardi Therapeutics Inc. | KORSUVA (CR845/difelikefalin tablets) - (KIND) | Pruritus in patients with Atopic dermatitis | Phase 2 | Trial Discontinued | Oral | Immunology |
| Tvardi Therapeutics Inc. | KORSUVA (CR845/difelikefalin) oral | Pruritus associated primary biliary cholangitis (PBC) | Phase 2 | Trial Completed | oral | Gastroenterology |
